GW Pharmaceuticals (GWPH) - Rolling submission initiated

08:20 EDT 22 Aug 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - GW Pharmaceuticals: GW Pharmaceuticals recently announced that a rolling NDA filing for Epidiolex in both Dravet syndrome and Lennox-Gastaut syndrome (LGS) is underway. The pre-clinical module has already been submitted, the clinical module is in process and the company expects to finish the chemistry, manufacturing and controls (CMC) section in October. GW anticipates the FDA will grant priority review status, which would enable a June 2018 PDUFA date. In Europe, pre-submission meetings were held with the EMA and the agency agreed that the company can file for approval for Dravet and LGS in a single application. An EMA filing is expected in Q417.
ISIN: US36197T1034

Original Article: GW Pharmaceuticals (GWPH) - Rolling submission initiated


More From BioPortfolio on "GW Pharmaceuticals (GWPH) - Rolling submission initiated"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...